

552,401

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number
WO 2004/089987 A1

(51) International Patent Classification⁷: **C07K 14/81**,
G01N 33/68, C07K 16/38, A61K 38/17

(21) International Application Number:
PCT/EP2004/003746

(22) International Filing Date: 7 April 2004 (07.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/461,560 8 April 2003 (08.04.2003) US

(71) Applicant (for all designated States except US): **GENOVA LTD.**; Canon's Court, 22 Victoria Street, Hamilton HM 12 (BM).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGOUD-PUY, Guilaine** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **BEDERR, Nassima** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin

(CH). **BOUGUELERET, Lydie** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **CUSIN, Isabelle** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **MAHE, Eve** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **NIKNEJAD, Anne** [CH/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **REFFAS, Samia** [CH/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS

SEQ ID NO:1

1 MKSSGLFPFL WLLALGTLAP WAVEGSGKSF KAGVCPPKKS AQCLRYKKPE CQSDWQCPGK
61 KRCCPDTCGI KCLDPVDTFN PTRRKPGKCP VTYGQCLMLN PPNFCEMDGQ CKRDLKCCMG
121 MCGKSCVSPV KA

SEQ ID NO:2

1 SGKSFKAGVC PPKKSAQCLR YKKPECQSDW QCPGKKRCCP DTCGIKKCLDP VDTFNPTRRK
61 PGKCPVTYGQ CLMLNPPNFC EMDGQCKRDL KCCMGKCGKS CVSPVKA

SEQ ID NO:3

YKKPECQSDW QCPGK

SEQ ID NO:4

KCLDPVDTFNP TR

(57) Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.

WO 2004/089987 A1



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.